Antifibrinolytics in major orthopaedic surgery

Journal of the American Academy of Orthopaedic Surgeons

Volumn 18, Issue 3, 2010, Pages 132-138

  Eubanks, Jason David ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77949791631     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/00124635-201003000-00002     Document Type: Review

References (51)

1. Samama CM: A direct antifibrinolytic agent in major orthopaedic surgery. Orthopaedics 2004;27(6 suppl):S675S680.
2. Guay J, Haig M, Lortie L, Guertin MC, Poitras B: Predicting blood loss in surgery for idiopathic scoliosis. Can J Anaesth 1994;41:775-781.
3. Meert KL, Kannan S, Mooney JF: Predictors of red cell transfusion in children and adolescents undergoing spinal fusion surgery. Spine (Phila Pa 1976) 2002;27:2137-2142.
4. Cole JW, Murray DJ, Snider RJ, Bassett GS, Bridwell KH, Lenke LG: Aprotinin reduces blood loss during spinal surgery in children. Spine (Phila Pa 1976) 2003; 28:2482-2485.
5. Thompson GH, Florentino-Pineda I, Poe-Kochert C: The role of amicar in decreasing perioperative blood loss in idiopathic scoliosis. Spine (Phila Pa 1976) 2005;30:S94-S99.
6. Copley LA, Richards BS, Safavi FZ, Newton PO: Hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine (Phila Pa 1976) 1999;24:219-222.
7. Murray DJ, Forbes RB, Titone MB, Weinstein SL: Transfusion management in pediatric and adolescent scoliosis surgery: Efficacy of autologous blood. Spine (Phila Pa 1976) 1997;22:27352740.
8. Neilipovitz DT: Tranexamic acid for major spinal surgery. Eur Spine J 2004; 13:S62-S65.
9. Hardy JF, Desroches J: Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth 1992;39:353365.
10. Center for Drug Evaluation and Research: Application number 74759. Aminocaproic acid approval letter. US Food and Drug Administration, 1998. Available at: http://129.128.185.122/ drugbank2/drugs/DB00513/fda-labels/ 433. Accessed December 14, 2009.
11. Cyklokapron tranexamic acid tablets and tranexamic acid injection: Antifibrinolytic agent. US Food and Drug Administration. Available at: http:// www.accessdata.fda.gov/drugsatfda-docs/label/2008/019281s0251bl.pdf. Accessed December 14, 2009.
12. Dunn CJ, Goa KL: Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999;57:1005-1032.
13. Righini M, Perrier A, De Moerloose P, Bounameaux H: D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008;6:10591071.
14. The Official Trasylol Aprotinin Injection by Bayer Pharmaceuticals Corporation. Bayer Healthcare Pharmaceuticals. Available at: http://www.trasylol.com. Accessed December 14, 2009.
15. Samama CM, Langeron O, Rosencher N, et al: Aprotinin versus placebo in major orthopaedic surgery: A randomized, double-blinded, doseranging study. Anesth Analg 2002;95: 287-295.
16. Laupacis A, Fergusson D: Drugs to minimize perioperative blood loss in cardiac sugery: Meta-analysis using perioperative blood loss as the outcome. The International Study of Peri-operative Transfustion (ISPOT) Investigators. Anesth Analg 1997;85:1258-1267.
17. Henry DA, Carless PA, Moxey AJ, et al: Anti-fibrinolytic use for minimizing perioperative allogenic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886.
18. Kristeller JL, Roslund BP, Stahl RF: Benefits and risks of aprotinin use during cardiac surgery. Pharmacotherapy 2008; 28:112-124.
19. Vander Salm TJ, Kaur S, Lancey RA, et al: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996;112:l098-1107.
20. Greilich PE, Brouse CF, Rinder CS, et al: Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 2004;100:225-233.
21. Williams GD, Bratton SL, Riley EC, Ramamoorthy C: Efficacy of epsilonaminocaproic acid in children undergoing cardiac surgery. J Cardiothorac Vase Anesth 1999;13: 304-308.
22. Chauhan S, Das SN, Bisoi A, Kale S, Kiran U: Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vase Anesth 2004; 18: 141-143.
23. Munoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ: Is epsilonaminocaproic acid as effective as aprotinin in reducing bleeding in cardiac surgery? A meta-analysis. Circulation 1999;99:81-89.
24. Murkin JM: Lessons learned in antifibrinolytic therapy: The BART trial. Semin Cardiothorac Vase Anesth 2009; 13:127-131.
25. Capdevila X, Calvet Y, Biboulet P, Biron C, Rubenovitch J, d'Athis F: Aprotinin decreases blood loss and homologous transfusions in patients undergoing major orthopedic surgery. Anesthesiology 1998;88:50-57.
26. Hiippala ST, Strid LJ, Wennerstrand MI, et al: Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997;84:839-844.
27. Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escoano F: Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion 2008;48:519-525.
28. Cid J, Lozano M: Tranexamic acid reduces allogenic red cell transfusions in patients undergoing total knee arthroplasty: Results of a meta-analysis of randomized controlled trials. Transfusion 2005;45:1302-1307.
29. Camarasa MA, OHe G, Serra-Prat M, et al: Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: A randomized clinical trial. Br J Anaesth 2006;96:576-582.
30. Harley BJ, Beaupré LD, Jones CA, Cinats JG, Guenther CR: The effect of epsilon aminocaproic acid on blood loss in patients who undergo primary total hip replacement: A pilot study. Can J Surg 2002;45:185-190.
31. Ray M, Hatcher S, Whitehouse SL, Crawford S, Crawford R: Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty: A prospective, randomized double-blind placebocontrolled study. J Thromb Haemost 2005;3:1421-1427.
32. Yamasaki S, Masuhara K, Fuji T: Tranexamic acid reduces postoperative blood loss in cementless total hip arthroplasty. J Bone Joint Surg Am 2005; 87:766-770.
33. Husted H, Blond L, Sonne-Holm S, Holm G, Jacobsen T, Gebhur P: Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: A prospective randomized double-blind study in 40 patients. Acta Orthop Scand 2003;74:665-669.
34. Johansson T, Pettersson LG, Lisander B: Tranexamic acid in total hip arthroplasty saves blood and money: A randomized, double-blind study in 100 patients. Acta Orthop 2005;76:314-319.
35. Engel JM, Hohaus T, Ruwoldt R, Menges T, Jiirgensen I, Hempelmann G: Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. Anesth Analg 2001;92:775-780.
36. Hayes A, Murphy DB, McCarroll M: The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth 1996;8:357-360.
37. Langdown AJ, Field J, Grote J, Himayat H: Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty 2000;15: 1009-1012.
38. Gill JB, Rosenstein A: The use of antifibrinolytic agents in total hip arthroplasty: A meta-analysis. J Arthroplasty 2006;21:869-873.
39. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G: Aprotinin decreases blood loss in patients undergoing revision in bilateral total hip arthroplasty. Anesth Analg 1995;80:343-348.
40. Jeserschek R, Ciar H, Aigner C, Rehak P, Primus B, Windhager R: Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: A prospective, double-blind, randomized and placebo-controlled study. J Bone Joint Surg Br 2003;85:174-177.
41. Florentino-Pineda I, Blakemore LC, Thompson GH, Poe-Kochert C, Adler P, Tripi P: The effect of epsilonaminocaproic acid on perioperative blood loss in patients with idiopathic scoliosis undergoing posterior spinal fusion: A preliminary prospective study. Spine (Phila Pa 1976) 2001;26:11471151.
42. Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM: A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. Anesth Analg 2001;93:82-87.
43. Shapiro F, Zurakowski D, Sethna NF: Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for duchenne muscular dystrophy scoliosis. Spine (Phila Pa 1976) 2007;32:2278-2283.
44. Florentino-Pineda I, Thompson GH, Poe-Kochert C, Huang RP, Haber LL, Blakemore LC: The effect of amicar on perioperative blood loss in idiopathic scoliosis: The results of a prospective, randomized double-blind study. Spine (Phila Pa) 2004;29:233-238.
45. Tzortzopoulou A, Cepeda MS, Schumann R, Carr DB: Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev 2008;3:CD006883.
46. Urban MK, Beckman J, Gordon M, Urqhart B, Boachie-Adjei O: The efficacy of antifibrinolytics in the reduction of blood loss during complex adult reconstructive spine surgery. Spine (Phila Pa 1976) 2001;26:1152-1156.
47. Lentschener C, Cottin P, Bouaziz H, et al: Reduction of blood loss and transfusion requirement by aprotinin in posterior lumbar spine fusion. Anesth Analg 1999;89:590-597.
48. Elwatidy S, Jamjoom Z, Elgamal E, Zakaria A, Turkistani A, El-Dawlatly A: Efficacy and safety of prophylatic large dose of tranexamic acid in spine surgery: A prospective, randomized, doubleblind, placebo-controlled study. Spine (Phila Pa 1976) 2008;33:2577-2580.
49. Slaughter TF, Greenberg CS: Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol 1997;56:3236.
50. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354: 353-365.
51. Zufferey P, Merquiol F, Laporte S, et al: Do antiofibrinolytics reduce allogenic blood transfusion in orthopedic surgery? Anesthesiology 2006;105:1034-1046.